|
Curriculum Vitae - Jodie Escobedo, M.D. | ||
|---|---|---|---|
|
EMPLOYMENT
EDUCATION BACHELOR OF ARTS IN PSYCHOLOGY
DOCTORATE OF MEDICINE
POSTGRADUATE MEDICAL TRAINING
ACTIVITIES
PRESENTATIONS
ADDITIONAL TRAINING
LICENSED IN THE STATE OF CALIFORNIA BOARD CERTIFICATION Diplomate American Board of Family Practice since 7/12/96
Assistant Clinical Professor, Department of Medicine
4/15/97 - 4/10/01
UCLA Medical Group Family Practice
Surgical Urgent Care Physician - part-time VITAS Healthcare Corporation of CA 4/2003 - 7/2006 Team Physician
Pacific Clinical Research LLC 1/2004 - 05/2005 Physician Member PROFESSIONAL AWARDS
Hugh Westbrook Community Service Award - VITAS Healthcare Corporation - 2005 PROFESSIONAL ACTIVITIES
ORGANIZED MEDICINE ACTIVITIES Blue Cross of
Quality Management Committee winter 2004 - present Patient Advocate Improvement Program (PAIP) advisory committee member 2004/5/6
Practice Affairs Committee Member 2005/6 PROFESSIONAL ORGANIZATIONS
COMMUNITY SERVICE
Volunteer Physician - September 2005 at the
Worked nights at a Katrina Refugee Shelter in the
"Talking To Your Kids About Sex" - Parent Education Talk for
PUBLICATIONS/BIBLIOGRAPHY Sunwoo, J., Brenman, A., Escobedo, J., Philpott, T., Allman, K., Mueller, J., Jaeger, J., Brown, L. and Cole, F.
CLINICAL RESEARCH EXPERIENCE 2005 AstraZeneca
Principle Investigator - A Randomized , Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of Rosuvastain( Crestor) 20 mg in the Primary prevention of cardiovascular events among subjects with low levels of LDL- Cholesterol and Elevated levels of Creactive protein. .
2005 Vivus
Principle Investigator -
2005 SankyoPrinciple Investigator A Randomized, Double Blind-Dummy, Placebo- Controlled, 26-week Dose Response Study of Rivogitaxone HCI (CS-011) with Active comparator (Plogitaxone HCI) in Subjects with Type 2 Diabetes.2005 PerlegenPrinciple Investigator - A Pharmacogenomic Sample Collection from Subjects with Type 2 Diabetes Treated with Pioglitazone or Rosiglitazone.2004 TakedaPrinciple Investigator - A Long-Term, Open-Label, Phase IIIA safety study of oral Take-559 (32mg QD) in the treatment of patient with Type 2 Diabetes Mellitus2004 TakedaPrinciple Investigator A Multi-Center Double Blind randomized placebo controlled Parallel study of the safety and efficacy of TAK-559 Compared to placebo in the treatment of patients with type 2 diabetes.2004- 2005 Lilly Principle Investigator - A Multi-Center Randomized trial to gather information on how effective Cymbalta (duloxetine) is in many different groups of depressed people.
Principle Investigator - Chronic Pain Screener Study 2002-2003
Sub- Investigator - ATHENA Study (ASCUS Triage & HPV: Evaluation and National Averages
Fall, Winter 2002
Sub Investigator - T.R.E.A.T. (Telithromycin Respiratory Effectiveness Assessment Trial).
Winter 2001
Sub Investigator- Southern California Research Institute under Candace J. Wilkinson, Ph.D. (310) 390-8481
|